KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
The University of Texas MD Anderson Cancer Center · City of Hope · +39 more institutions
Indexed incrossrefpubmed
Abstract
Background
.
Methods
p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Citation impact
1,673
total citations
- FWCI
- 90.53
- Percentile
- 100%
- References
- 40
Citations per year
Authors
34- DSDavid S. HongCorresponding
The University of Texas MD Anderson Cancer Center, City of Hope
- MFMarwan Fakih
City of Hope
- JHJohn H. Strickler
City of Hope, Duke Medical Center
- JDJayesh Desai
The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, City of Hope
- GAGregory A. Durm
City of Hope, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis
Topics & keywords
Topics
Keywords
- KRAS
- Radiochemistry
- Nuclear medicine
- Cancer research
- Chemistry
- Computer science
- Medicine
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.